Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 3/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | PIEZO1 | Q92508 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13610472 | 0.82 | RAB9A (0.46) | RAB9ACYP1A2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL13610475 | 0.82 | SMN1; SMN2 (0.47) | RAB9ACYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13610497 | 0.74 | CYP1A2 (0.41) | RAB9ACYP1A2CYP2D6VNN1CYP3A4 | |
| SCHEMBL13610491 | 0.73 | TSHR (0.37) | RAB9ACYP1A2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL13610488 | 0.73 | TDP1 (0.43) | RAB9ACYP1A2CYP2D6CYP3A4CYP2C19 | |
| SCHEMBL13610498 | 0.72 | CYP1A2 (0.35) | RAB9ACYP1A2CYP2D6VNN1DAO | |
| SCHEMBL13610342 | 0.72 | NPC1 (0.36) | RAB9ANPC1SMN1; SMN2TERTHTT | |
| SCHEMBL13610340 | 0.72 | TERT (0.48) | RAB9ACYP1A2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL13610495 | 0.70 | DAO (0.40) | RAB9ACYP1A2VNN1DAOCYP3A4 | |
| SCHEMBL13610415 | 0.70 | MAPT (0.46) | RAB9ACYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742635-B1 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | ACEA BIOSCIENCES INC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-8334316-B2 | Substituted organosulfur compounds and methods of using thereof | ACEA BIOSCIENCES, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334316-B2 | Substituted organosulfur compounds and methods of using thereof | ACEA BIOSCIENCES, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-7622507-B2 | Substituted organosulfur compounds and methods of using thereof | ACEA BIOSCIENCES INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622507-B2 | Substituted organosulfur compounds and methods of using thereof | ACEA BIOSCIENCES INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090192146-A1 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | ACEA BIOSCIENCES, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090192146-A1 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | ACEA BIOSCIENCES, INC. (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192146-A1 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | TST, CTH, CBS | RAB9A 4609/4885CYP1A2 3924/4885CYP2D6 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.